Stifel lowered the firm’s price target on SLB (SLB) to $60 from $62 and keeps a Buy rating on the shares. Though international growth rates are slowing, the firm says Q3 results, Q4 guidance, and the 2025 outlook support its belief that the risk/reward in the shares remains favorable and that SLB is well positioned to deliver solid growth and robust free cash flow over the next few years.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLB:
- SLB price target lowered to $61 from $63 at Barclays
- SLB price target lowered to $62 from $74 at Evercore ISI
- Netflix reports Q3 beat, CVS CEO Lynch steps down: Morning Buzz
- SLB Earnings: SLB’s Q3 Earnings Rise amid Cautious Market Conditions
- Morning Movers: CVS Health sinks following CEO change, weak guidance